671 related articles for article (PubMed ID: 15929121)
61. Surgical management of bisphosphonate induced osteonecrosis of the jaws.
Williamson RA
Int J Oral Maxillofac Surg; 2010 Mar; 39(3):251-5. PubMed ID: 20015614
[TBL] [Abstract][Full Text] [Related]
62. Bisphosphonate-induced osteonecrosis of the jaw (ONJ): Incidence and risk factors in patients with breast cancer and gynecological malignancies.
Fehm T; Beck V; Banys M; Lipp HP; Hairass M; Reinert S; Solomayer EF; Wallwiener D; Krimmel M
Gynecol Oncol; 2009 Mar; 112(3):605-9. PubMed ID: 19136147
[TBL] [Abstract][Full Text] [Related]
63. Osteonecrosis of the jaws and bisphosphonate treatment in cancer patients.
Wutzl A; Eisenmenger G; Hoffmann M; Czerny C; Moser D; Pietschmann P; Ewers R; Baumann A
Wien Klin Wochenschr; 2006 Aug; 118(15-16):473-8. PubMed ID: 16957978
[TBL] [Abstract][Full Text] [Related]
64. Jaw avascular osteonecrosis after treatment of multiple myeloma with zoledronate.
Lobato JV; Maurício AC; Rodrigues JM; Cavaleiro MV; Cortez PP; Xavier L; Botelho C; Hussain NS; Santos JD
J Plast Reconstr Aesthet Surg; 2008; 61(1):99-106. PubMed ID: 18068658
[TBL] [Abstract][Full Text] [Related]
65. Bony changes in the jaws of rats treated with zoledronic acid and dexamethasone before dental extractions mimic bisphosphonate-related osteonecrosis in cancer patients.
Sonis ST; Watkins BA; Lyng GD; Lerman MA; Anderson KC
Oral Oncol; 2009 Feb; 45(2):164-72. PubMed ID: 18715819
[TBL] [Abstract][Full Text] [Related]
66. Bisphosphonates and time to osteonecrosis development.
Palaska PK; Cartsos V; Zavras AI
Oncologist; 2009 Nov; 14(11):1154-66. PubMed ID: 19897878
[TBL] [Abstract][Full Text] [Related]
67. Prosthodontic treatment of a patient with bisphosphonate-induced osteonecrosis of the jaw using a removable dental prosthesis with a heat-polymerized resilient liner: a clinical report.
Göllner M; Holst S; Fenner M; Schmitt J
J Prosthet Dent; 2010 Apr; 103(4):196-201. PubMed ID: 20362762
[TBL] [Abstract][Full Text] [Related]
68. Bisphosphonate-associated osteonecrosis of the jaw in Ontario: a survey of oral and maxillofacial surgeons.
Khan AA; Rios LP; Sándor GK; Khan N; Peters E; Rahman MO; Clokie CM; Dore E; Dubois S
J Rheumatol; 2011 Jul; 38(7):1396-402. PubMed ID: 21498483
[TBL] [Abstract][Full Text] [Related]
69. Does avascular necrosis of the jaws in cancer patients only occur following treatment with bisphosphonates?
Lenz JH; Steiner-Krammer B; Schmidt W; Fietkau R; Mueller PC; Gundlach KK
J Craniomaxillofac Surg; 2005 Dec; 33(6):395-403. PubMed ID: 16253510
[TBL] [Abstract][Full Text] [Related]
70. Use of bisphosphonates for the treatment of osteonecrosis as a complication of therapy for childhood acute lymphoblastic leukaemia (ALL).
Kotecha RS; Powers N; Lee SJ; Murray KJ; Carter T; Cole C
Pediatr Blood Cancer; 2010 Jul; 54(7):934-40. PubMed ID: 20127847
[TBL] [Abstract][Full Text] [Related]
71. Managing the care of patients with bisphosphonate-associated osteonecrosis: an American Academy of Oral Medicine position paper.
Migliorati CA; Casiglia J; Epstein J; Jacobsen PL; Siegel MA; Woo SB
J Am Dent Assoc; 2005 Dec; 136(12):1658-68. PubMed ID: 16383047
[TBL] [Abstract][Full Text] [Related]
72. Toward new horizons: the future of bisphosphonate therapy.
Lipton A
Oncologist; 2004; 9 Suppl 4():38-47. PubMed ID: 15459428
[TBL] [Abstract][Full Text] [Related]
73. Bisphosphonate therapy for patients with breast carcinoma.
Plunkett TA; Rubens RD
Cancer; 2003 Feb; 97(3 Suppl):854-8. PubMed ID: 12548586
[TBL] [Abstract][Full Text] [Related]
74. Bisphosphonate-induced osteonecrosis of the jaws, bone markers, and a hypothesized candidate gene.
Lehrer S; Montazem A; Ramanathan L; Pessin-Minsley M; Pfail J; Stock RG; Kogan R
J Oral Maxillofac Surg; 2009 Jan; 67(1):159-61. PubMed ID: 19070762
[TBL] [Abstract][Full Text] [Related]
75. Safety and pain palliation of zoledronic acid in patients with breast cancer, prostate cancer, or multiple myeloma who previously received bisphosphonate therapy.
Vogel CL; Yanagihara RH; Wood AJ; Schnell FM; Henderson C; Kaplan BH; Purdy MH; Orlowski R; Decker JL; Lacerna L; Hohneker JA
Oncologist; 2004; 9(6):687-95. PubMed ID: 15561812
[TBL] [Abstract][Full Text] [Related]
76. Bisphosphonate-related osteonecrosis of the jaws: a review of 34 cases and evaluation of risk.
Kos M; Kuebler JF; Luczak K; Engelke W
J Craniomaxillofac Surg; 2010 Jun; 38(4):255-9. PubMed ID: 19592261
[TBL] [Abstract][Full Text] [Related]
77. Unusual case of a conservatively treated pathological fracture after sequestrectomy in a patient with long-term oral bisphosphonate use.
Kuijpers SC; van Roessel EW; van Merkesteyn JP
J Craniomaxillofac Surg; 2011 Jan; 39(1):69-72. PubMed ID: 20435482
[TBL] [Abstract][Full Text] [Related]
78. New generation of bisphosphonates: broad clinical utility in breast and prostate cancer.
Rosen LS
Oncology (Williston Park); 2004 May; 18(5 Suppl 3):26-32. PubMed ID: 15202585
[TBL] [Abstract][Full Text] [Related]
79. Bisphosphonate-related osteonecrosis of the maxilla and sinusitis maxillaris.
Maurer P; Sandulescu T; Kriwalsky MS; Rashad A; Hollstein S; Stricker I; Hölzle F; Kunkel M
Int J Oral Maxillofac Surg; 2011 Mar; 40(3):285-91. PubMed ID: 21163624
[TBL] [Abstract][Full Text] [Related]
80. [A case of breast cancer with extensive osteonecrosis of maxilla induced by a bisphosphonate].
Tanaka Y; Koga M; Yokomizo Y; Inokuchi S; Koga C; Kusukawa J
Gan To Kagaku Ryoho; 2010 Apr; 37(4):681-5. PubMed ID: 20414026
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
